Company Overview of Transcept Pharmaceuticals, Inc.
As of October 30, 2014, Transcept Pharmaceuticals, Inc. was acquired by Paratek Pharmaceuticals, Inc., in a reverse merger transaction. Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. The company principal product include Intermezzo sublingual tablet C-IV, a sublingual formulation of zolpidem for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Its lead product candidate is TO-2070, a rapidly absorbed treatment for acute migraine. The company has a collaboration agreement with Pur...
1003 West Cutting Boulevard
Point Richmond, CA 94804
Founded in 2002
Key Executives for Transcept Pharmaceuticals, Inc.
Transcept Pharmaceuticals, Inc. does not have any Key Executives recorded.
Transcept Pharmaceuticals, Inc. Key Developments
Transcept Pharmaceuticals, Inc.(NasdaqGM:TSPT) dropped from NASDAQ Composite Index
Oct 30 14
Transcept Pharmaceuticals, Inc. will be removed from the NASDAQ Composite Index.
Transcept Pharmaceuticals, Inc., Special/Extraordinary Shareholders Meeting, Oct 28, 2014
Oct 20 14
Transcept Pharmaceuticals, Inc., Special/Extraordinary Shareholders Meeting, Oct 28, 2014.
Transcept Pharmaceuticals Declares Special Dividend, Payable on October 29, 2014
Oct 14 14
Transcept Pharmaceuticals declared a special dividend, in connection with its merger with Paratek Pharmaceuticals, in the initial cash amount of $0.6674 per share on Transcept's common stock and the right to receive certain contingent cash amounts, in the future, on a pro rata basis. All payments will be made to stockholders of record at the close of business on October 24, 2014. The initial cash payment will be made on October 29, 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 1, 2014